Feedback

X
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy

Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy

0 Ungluers have Faved this Work
Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.

This book is included in DOAB.

Why read this book? Have your say.

You must be logged in to comment.

Rights Information

Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.

Downloads

This work has been downloaded 27 times via unglue.it ebook links.
  1. 27 - pdf (CC BY) at Unglue.it.

Keywords

  • 2019 Beers criteria
  • 5’nuclease assay
  • abacavir
  • acute kidney injury
  • adverse drug reaction
  • adverse drug reactions
  • Aged
  • aged, 80 and over
  • allopurinol
  • antidepressants
  • antiepileptic drugs
  • antipsychotics
  • appropriateness
  • bleeding
  • Children
  • chronic
  • clinical pharmacist
  • clozapine
  • CNV
  • copy number variation
  • cost-effectiveness
  • CYP1A2
  • CYP2D6
  • CYP2D7P
  • CYP2D8P
  • Cytochrome P450
  • Cytochromes
  • deprescribing
  • deprescriptions
  • determinants
  • digital decision-support
  • digital health
  • DOACs
  • drug hypersensitivity
  • drug information service
  • drug interaction checkers
  • drug metabolization
  • drug–drug interactions
  • drug–gene interactions
  • early biomarker
  • Economics, finance, business & management
  • Electronic Medical Record
  • electronic prescribing
  • emergency department
  • Ethiopia
  • Exosomes
  • extracellular vesicles
  • flucloxacillin
  • general practice
  • genotyping
  • Health Outcomes
  • Health Services Research
  • high resolution melting
  • HLA
  • hospital pharmacy service
  • HRM
  • Industry & industrial studies
  • loxapine
  • Manufacturing industries
  • medication adherence
  • medication optimization
  • medication reconciliation
  • medication review
  • medication-based risk score
  • medicine
  • microvesicles
  • multimorbidity
  • Nursing Homes
  • olanzapine
  • older adults
  • older patients
  • outpatient
  • personalized medicine
  • persons with diabetes
  • Pharmaceutical industries
  • pharmacogene expression
  • Pharmacogenetics
  • Pharmacogenomics
  • phenprocoumon
  • plasma neutrophil gelatinase-associated lipocalin
  • polypharmacy
  • population-based
  • potentially inappropriate medication use
  • Prevalence
  • process evaluation
  • Quality of life
  • shared medication record
  • SLCO1B1
  • soluble urokinase plasminogen activator receptor
  • Thromboembolism
  • Utility
  • Youth

Links

DOI: 10.3390/books978-3-0365-5161-6

Editions

edition cover

Share

Copy/paste this into your site: